Abstract:Abstract Background Lamotrigine is approved as a maintenance therapy for bipolar I disorder in many countries, including China in 2021. This study evaluated the efficacy and safety of lamotrigine in controlling relapse and/or recurrence of mood episodes in Chinese patients with bipolar I disorder. Methods Patients aged ≥ 18 years with bipolar I disorder who met response criteria (Clinical Global Impression–Severity [CGI-S] score of ≤ 3 for ≥ 4 consecutive weeks) during treatment with lamotrigine in a 6–16 week open-label (OL) phase, and who were maintained for ≥ 1 week on lamotrigine 200 mg/day monotherapy, were randomised (1:1) to continue receiving lamotrigine 200 mg/day or switch to placebo in a 36-week randomised double-blind (RD) phase. The primary efficacy outcome measure was time from entry into the RD phase to intervention for relapse and/or recurrence of a mood episode (TIME). Post hoc analyses assessed the impact of OL baseline mood severity on TIME. Safety assessments were conducted throughout the study. Results Of 420 patients treated in the OL phase, 264 were randomised to receive lamotrigine (n = 131) or placebo (n = 133). Overall, 112 patients had an intervention for relapse and/or recurrence of a mood episode (lamotrigine, n = 50/130 [38.5%]; placebo, n = 62/133 [46.6%]), with no significant difference in TIME between groups (adjusted hazard ratio [95% confidence interval (CI)] 0.93 [0.64, 1.35]; p = 0.701). Post hoc analyses indicated a significant difference in TIME, favouring lamotrigine over placebo, for patients with baseline CGI-S score ≥ 4 (hazard ratio [95% CI] 0.52 [0.30, 0.89]; p = 0.018) and with baseline Hamilton Depression Rating Scale ≥ 18 or Young Mania Rating Scale ≥ 10 (0.44 [hazard ratio [95% CI] 0.25, 0.78]; p = 0.005). Lamotrigine was well tolerated with no new safety signals. Conclusions Lamotrigine was not significantly superior to placebo in preventing relapse and/or recurrence of mood episodes in this study of Chinese patients with bipolar I disorder but post hoc analyses suggested a therapeutic benefit in patients with moderate/severe mood symptoms at baseline. The discrepancy between these findings and the positive findings of the pivotal studies may be attributable to the symptom severity of the bipolar patients recruited, a high dropout rate, and the comparatively short duration of the RD phase rather than race/ethnicity differences. Clinical trial registration ClinicalTrial.gov Identifier NCT01602510; 21st May 2012; https://clinicaltrials.gov/ct2/show/NCT01602510.

Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report

Lamotrigine Therapy for Bipolar Depression: Analysis of Self-Reported Patient Data

The efficacy of lamotrigine in bipolar disorder: A systematic review and meta‐analysis

Effectiveness of Lamotrigine in Maintaining Symptom Control in Pediatric Bipolar Disorder

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lamotrigine in the Maintenance Treatment of Chinese Adult Patients with Bipolar I Disorder

Lamotrigine Adjunctive Therapy To Lithium And Divalproex In Depressed Patients With Rapid Cycling Bipolar Disorder And A Recent Substance Use Disorder: A 12-Week, Double-Blind, Placebo-Controlled Pilot Study

Comparisons of the Tolerability and Sensitivity of Lamotrigine in the Treatment of Schizophrenia,bipolar Depression and Major Depressive Disorder: a Systematic Review

Enhanced Working and Verbal Memory after Lamotrigine Treatment in Pediatric Bipolar Disorder.

Aripiprazole in Combination with Lamotrigine for the Long‐term Treatment of Patients with Bipolar I Disorder (manic or Mixed): a Randomized, Multicenter, Double‐blind Study (CN138‐392)

Acute neural effects of the mood stabiliser lamotrigine on emotional processing in healthy volunteers: a randomised control trial

An open-labeled, randomized comparative study of lamotrigine and lithium in treatment of bipolar depression

Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder

Effect of Lamotrigine on Quality of Life in Patients with Newly Diagnosed Epilepsy

Effect of Genetic Polymorphisms of ABCB1, ABCG2, and SLC22A1 on the Steady-State Plasma Concentrations of Lamotrigine in Treatment-Resistant Depressed Patients Treated With Lamotrigine Augmentation Therapy

Lamotrigine in mood disorders: Flash survey on prescribing habits and blood tests practices

Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode

P.2.e.029 Levetiracetam in the Management of Bipolar Depression: a Randomized, Double-Blind, Placebo Controlled Trial

Efficacy and Safety of Quetiapine-Xr As Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: a Randomized, Placebo-Controlled Trial.

Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression

Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study

Longer-term open-label study of adjunctive riluzole in treatment-resistant depression